GVHD Prophylaxis in Allogeneic Stem Cell Transplantation

All patients received conventional regimen such as myeloablative/reduced-intensity conditionings, and were classified based on criteria described by Giralt et al. [12 (link)]. Cyclosporine A (CsA) + mycophenolate mofetil (MMF) + a short course of methotrexate (MTX) were administered to the patients undergoing human leukocyte antigen (HLA)-matched sibling donor (MSD) transplant for GVHD prophylaxis. After January 2019, CsA + MMF + MTX + anti-thymocyte globulin (ATG) (ThymoglobulinⓇ, Genzyme, Cambridge, MA) were administered for 1.5 mg/kg i.v. on day-3, -2 and -1 to the MSD transplant patients whose age ≥ 45 years, and CsA + MMF + MTX + ATG (2.5 mg/kg i.v. on day-4, -3, -2 and -1) were administered to the patients undergoing haploidentical donor [13 (link)] transplants for GVHD prophylaxis, some haploidentical recipients received transplant cyclophosphamide 50 mg/kg on day + 3.